EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Metabolic Reprogramming: A Crucial Contributor to Anticancer Drug Resistance

Yunhan Zhu, Weijie Yan, Lingfeng Tong, Jie Yang, Shengfang Ge, Jiayan Fan, Renbing Jia, Xuyang Wen

MedComm · 2025-09 · 6 (9)

DOI: 10.1002/mco2.70358 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 06.09.2025. Verfasst von Yunhan Zhu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 269 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer metabolic reprogramming is a fundamental hallmark that enables tumor cells to sustain their malignant behaviors. Beyond its role in supporting growth, invasion, and migration, metabolic rewiring actively contributes to anticancer drug resistance. Cancer cells not only reshape their own metabolism but also engage in aberrant metabolic crosstalk with nonmalignant components within the tumor microenvironment (TME). These metabolic alterations create multiple barriers to the efficacy of drug therapies, including chemotherapy, targeted therapy, and immunotherapy. Despite growing evidence, an integrated understanding of how metabolic reprogramming contributes to the development of drug resistance and how it may be therapeutically targeted to overcome the resistance remains incomplete. This review summarizes recent progresses in tumor‐intrinsic and TME‐associated metabolic alterations that contribute to drug resistance by sustaining metabolic needs and modulating nonmetabolic processes and explores the upstream regulatory mechanisms driving these changes, focusing particularly on glucose, lipid, and amino acid metabolism. We also discuss the current advances in the integration of small molecule inhibitors targeting cancer metabolism to address drug resistance. By consolidating mechanistic insights and therapeutic opportunities, this review highlights metabolic reprogramming as a promising intervention point to overcome anticancer drug resistance.

Schlagwörter

Stichwörter der Autor:innen

cancer metabolismdrug resistancemetabolic targeted strategiestumor microenvironment

Autor:innen und Institutionen

  • Department of Ophthalmology Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China.
  • Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology Shanghai China.
  • State Key Laboratory of Eye Health, Department of Ophthalmology, Shanghai Ninth People's Hospital Shanghai Jiao Tong University School of Medicine Shanghai China.
  • Engineering Research Center of Techniques and Instruments for Diagnosis and Treatment of Congenital Heart Disease, Ministry of Education Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China.

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Commission of Shanghai Municipality

Zitieren

APA

Zhu, Y., Yan, W., Tong, L., Yang, J., Ge, S., Fan, J., Jia, R., & Wen, X. (2025). Metabolic Reprogramming: A Crucial Contributor to Anticancer Drug Resistance. MedComm, 6(9). https://doi.org/10.1002/mco2.70358

Vancouver

Zhu Y, Yan W, Tong L, Yang J, Ge S, Fan J, et al. Metabolic Reprogramming: A Crucial Contributor to Anticancer Drug Resistance. MedComm. 2025;6(9). doi:10.1002/mco2.70358

BibTeX
@article{Zhu2025,
  author = {Zhu, Yunhan and Yan, Weijie and Tong, Lingfeng and Yang, Jie and Ge, Shengfang and Fan, Jiayan and Jia, Renbing and Wen, Xuyang},
  title = {Metabolic Reprogramming: A Crucial Contributor to Anticancer Drug Resistance},
  journal = {MedComm},
  year = {2025},
  volume = {6},
  number = {9},
  doi = {10.1002/mco2.70358}
}
Kostenlos starten →